Lipoprotein(a) and the risk of cardiovascular disease in the European population: Results from the BiomarCaRE consortium

European Heart Journal

Volumn 38, Issue 32, 2017, Pages 2490-2498

  Waldeyer, Christoph ^a   Makarova, Nataliya ^a,b   Zeller, Tanja ^a,b   Schnabel, Renate B ^a,b   Brunner, Fabian J ^a   Jørgensen, Torben ^c,d,e   Linneberg, Allan ^c,d,f   Niiranen, Teemu ^g   Salomaa, Veikko ^g   Jousilahti, Pekka ^g   Yarnell, John ^h   Ferrario, Marco M ⁱ   Veronesi, Giovanni ⁱ   Brambilla, Paolo ^j   Signorini, Stefano G ^j   Iacoviello, Licia ^k   Costanzo, Simona ^k   Giampaoli, Simona ^l   Palmieri, Luigi ^l   Meisinger, Christa ^m   Thorand, Barbara ^m   Kee, Frank ^h   Koenig, Wolfgang ^b,n,o   Ojeda, Francisco ^a   Kontto, Jukka ^g   Landmesser, Ulf ^b,p,q   Kuulasmaa, Kari ^g   Blankenberg, Stefan ^a,b   more..

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Research Centre for Prevention and Health   (Denmark)

^e AALBORG UNIVERSITY   (Denmark)

^f Rigshospitalet   (Denmark)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

ⁱ UNIVERSITY OF INSUBRIA   (Italy)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k IRCCS NEUROMED   (Italy)

^l ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^m INSTITUTE OF EPIDEMIOLOGY   (Germany)

ⁿ UNIVERSITY HOSPITAL ULM   (Germany)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q BERLIN INSTITUTE OF HEALTH   (Germany)

more..

Author keywords

BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe); Cardiovascular risk; Lipoprotein(a); MORGAM (MONICA Risk Genetics Archiving and Monograph); Mortality

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; EUROPEAN; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL; DEMOGRAPHY; EPIDEMIOLOGY; EUROPE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ADULT; BIOMARKERS; CARDIOVASCULAR DISEASES; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RESIDENCE CHARACTERISTICS; RISK ASSESSMENT;

EID: 85028327094     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx166     Document Type: Article

References (35)

1. Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a]. Structural properties. J Biol Chem 1983;258:4582-4589.
2. Mbewu AD, Durrington PN. Lipoprotein (a): Structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990;85:1-14.
3. Scanu AM. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988;112:1045-1047.
4. Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672-679.
5. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-2339.
6. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423.
7. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31:2844-2853.
8. Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): Prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 2014;64:851-860.
9. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL. Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015;386:1472-1483.
10. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, doseranging trials. Lancet 2016;388:2239-2253.
11. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein( a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008;117:176-184.
12. Mellwig KP, Schatton C, Biermann B, Kottmann T, Horstkotte D, van Buuren F. [Lipoprotein(a): Influence on cardiovascular manifestation]. Clin Res Cardiol Suppl 2015;10:33-38.
13. Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, den Ruijter H, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S. BiomarCaRE: Rationale and design of the European BiomarCaRE project including 300, 000 participants from 13 European countries. Eur J Epidemiol 2014;29:777-790.
14. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, Perola M, Peltonen L, Shields D, Tunstall-Pedoe H, Kuulasmaa K. MORGAM (an international pooling of cardiovascular cohorts). Int J Epidemiol 2005;34:21-27.
15. Simo JM, Camps J, Gomez F, Ferre N, Joven J. Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. Clin Biochem 2003;36:129-134.
16. Pigott T, Williams R, Polanin J. Combining individual participant and aggregated data in a meta-analysis with correlational studies. Res Synth Methods 2012;3:257-268.
17. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos CH, Wood DA, Zamorano JL, Cooney MT. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058.
18. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-276.
19. Bender R, Lange S. Adjusting for multiple testing-when and how?. J Clin Epidemiol 2001;54:343-349.
20. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
21. Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassification improvement: Computation, interpretation, and controversies: A literature review and clinician's guide. Ann Intern Med 2014;160:122-31.
22. Pencina MJ, D'agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
23. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-1701.
24. Antolini L, Nam B-H, D'agostino RB. Inference on correlated discrimination measures in survival analysis: A nonparametric approach. Commun Stat Theory Methods 2004;33:2117-2135.
25. Jonckheere AR. A distribution-free k-sample test again ordered alternatives. Biometrika 1954;41:133-145.
26. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904-910.
27. Contois JH, Wu AH, Li Z, Feroze AH, Grunenberger F, Haller J, DeGroot L, Lammi-Keefe CJ. Distribution of serum apolipoproteins A-I and B and lipoprotein( a) in European elderly. The SENECA study. Clin Chim Acta 2000;295:1-12.
28. Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, Vaarhorst A, Kangas AJ, Lyytikäinen LP, Pirinen M, Pool R, Sarin AP, Soininen P, Tukiainen T, Wang Q, Tiainen M, Tynkkynen T, Ala-Korpela M. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun 2016;7:11122.
29. Ariyo AA, Thach C, Tracy R. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003;349:2108-2115.
30. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G. Woodward M, Rumley A, Lowe GDO, Danesh J, Gudnason V. Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data. Arch Intern Med 2008;168:598-608.
31. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, Dagenais GR. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men?. The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-525.
32. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57.
33. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-2506.
34. Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol 2010;4:240-247.
35. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-353.